BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

Spruce Biosciences hopes two rounds of financing will be enough to deliver pivotal data for its lead program, which takes a non-steroidal approach to treating endocrine disorders such as classic congenital adrenal hyperplasia (CAH). Omega...
BioCentury | Mar 3, 2016
Distillery Therapeutics

Therapeutics: Corticotropin-releasing factor receptor 1 (CRHR1; CRFR1)

Neurology INDICATION: Anxiety In vitro and mouse studies identified a CRHR1 antagonist that could help treat anxiety. Chemical synthesis and in vitro testing of benzimidazole analogs identified a compound that bound CRHR1 with a Ki...
BioCentury | Jun 9, 2015
Clinical News

FDA places partial clinical hold on Neurocrine's NBI-77860

Neurocrine BioSciences Inc. (NASDAQ:NBIX) fell $2.27 to $43.01 in after-hours trading on Monday after it said FDA placed a partial clinical hold on NBI-77860 , its candidate to treat congenital adrenal hyperplasia (CAH). The company has...
BioCentury | Jan 5, 2015
Clinical News

NBI-77860: Phase I/II started

Neurocrine began the open-label Phase I/II 1401 Study to evaluate single ascending doses of NBI-77860 in about 15 adolescent females with CAH. Neurocrine Biosciences Inc. (NASDAQ:NBIX), San Diego, Calif. Product: NBI-77860 Business: Endocrine/Metabolic Molecular target:...
BioCentury | Dec 4, 2014
Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations to...
BioCentury | Sep 18, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Aquaporin-4 (AQP4); corticotropin-releasing factor 1 (CRF1); corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) Rat studies suggest inhibiting CRFR1 signaling could help prevent hypoxia-induced cerebral edema,...
BioCentury | Oct 24, 2013
Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...
BioCentury | Aug 22, 2013
Cover Story

Deep pockets

The B class of GPCRs is brimming with therapeutic targets, but thus far, development of small molecule drugs has been stymied. New studies reporting the first-ever crystal structures of members of the family could change...
BioCentury | Aug 22, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Crystal structure of corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) bound to a small molecule antagonist A crystal structure of an antagonist-bound...
BioCentury | Apr 15, 2013
Company News

Neurocrine, Janssen Pharmaceutica Inc. deal

NBIX received an undisclosed milestone from Janssen for starting a Phase I trial of NBI-30775 (R121919), a corticotropin releasing factor (CRF) receptor antagonist for anxiety and depression (see C5 ). Neurocrine Biosciences Inc. (NBIX), San...
Items per page:
1 - 10 of 51